US 9,050,094

Application 12/407,709 · Granted Jun 9, 2015

Methods and devices for passive residual lung volume reduction and functional lung volume expansion

Estimated expiration

October 6, 2029

2y 320d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Mar 12, 2007
+ 20 years
Mar 12, 2027
PTA +939d
Oct 6, 2029
No TD
—
Final
Oct 6, 2029

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
March 19, 2009
Earliest effective filing
March 12, 2007
Issue date
June 9, 2015
PTA
+939 days
Base expiry (before PTA)
March 12, 2027

March 12, 2007 + 20 years = March 12, 2027 + 939 PTA days = October 6, 2029

  • Continuation-in-part of application PCTUS2008056706, filed Mar 12, 2008
  • Continuation of application 11/685,008, filed Mar 12, 2007

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 12/407,709 · US 9,050,094

PatentReply compiles the prosecution history behind US 9,050,094: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US9050094

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.